LLY
xyz:
equity
· Hyperliquid
—
Equity perp — Hyperliquid synthetic derivative. For real-time exchange pricing, turn off the Crypto toggle and search the bare equity ticker.
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, such as Cyramza for the second-line treatment of gastric cancer or gastro-esophageal junction adenocarcinoma; Erbitux for colorectal cancers and head and neck cancers; Inluriyo for breast cancer; Jaypirca for chronic lymphocytic leukemia or small lymphocytic lymphoma; Retevmo for the treatment of metastatic NSCLC; TYVYT for classic hodgkin's lymphoma; and Verzenio for breast cancer. In addition, the company offers immunology products, which include Ebglyss for severe atopic dermatitis; Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Omvoh for ulcerative colitis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. Further, it provides Emgality for migraine prevention and episodic cluster headache, as well as Kisubla for symptomatic Alzheimer's disease. The company has collaborations with Boehringer Ingelheim Pharmaceuticals, Inc. for the Jardiance product family; and F. Hoffmann-La Roche Ltd and Genentech, Inc. for lebrikizumab, as well as license agreements with Almirall, S.A. for Ebglyss; and Chugai Pharmaceutical Co., Ltd for orforglipron; and strategic collaboration with Ascidian Therapeutics for discovery and development of therapies for undisclosed monogenic kidney diseases. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Mark Price
$1126.00
24h Change
-1.21%
Funding (8h)
+0.0034%
Open Interest
4,063
24h Volume
$1.12M
Oracle Price
$1125.20
Mark − Oracle
+0.0924%
Prev Day Close
$1139.80
As of (UTC)
2026-06-15 18:54:44
Daily candles — last 83 days
Funding rate history — last 7 days (8h cycles)
Positive funding = longs paying shorts (long-crowded). Negative = shorts paying longs (short-crowded).
Peers — same category
| Coin | Mark | 24h % |
|---|---|---|
| SPCX | $186.86 | +12.30% |
| MU | $1092.80 | +8.14% |
| SNDK | $2095.50 | +4.48% |
| SKHX | $1590.20 | +5.96% |
| INTC | $128.03 | +0.05% |
News headlines Yahoo Finance, 1h cache
-
Should You Buy Eli Lilly Stock Now or Wait for a Dip?
2026-06-15 16:50 · Yahoo
-
This Financial Bellwether Bankrolls A Breakout
2026-06-15 16:14 · Yahoo
-
Novo Nordisk Gains 7% in a Week: How Should Investors Play the Stock?
2026-06-15 14:40 · Yahoo
-
Is Pfizer's Discounted Valuation a Buying Opportunity or a Value Trap?
2026-06-15 14:04 · Yahoo
-
These Are 5 Of The Best Stocks To Buy Or Watch Now
2026-06-15 13:26 · Yahoo
-
ENDO 2026 Oral Presentation Highlights Comparative Clinical Data for Entera’s Breakthrough Single Tablet EB613 (First-in-Class Oral PTH(1-34) Anabolic for Osteoporosis)
2026-06-15 12:45 · Yahoo
-
Lilly scores early positive data for new JAK drug
2026-06-15 09:43 · Yahoo
-
India's Electronics Mart eyes new markets as tech hubs fear job losses
2026-06-15 05:31 · Yahoo
-
Eli Lilly JAK2 Data Highlights Pipeline Beyond Obesity And Valuation Upside
2026-06-15 03:10 · Yahoo
-
3 Reasons to Buy Eli Lilly Stock Like There's No Tomorrow
2026-06-14 12:35 · Yahoo